|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In a large patient cohort we identified that especially combined high expression of Ang-2 and VEGFA predicted poor overall survival of GBM patients.
|
29644004 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis.
|
30327956 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
VEGF mediated GDNF-induced angiogenesis in human glioblastoma.
|
30176167 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF)-A and VEGF receptor expression in the peritumoral brain zone (PBZ) differs from that in the tumor core (TC) of glioblastoma.
|
30165233 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiogenesis mediated by vascular endothelial growth factor (VEGF) is a hallmark of glioblastoma.
|
29507055 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bevacizumab is an anti-vascular endothelial growth factor antibody used in the treatment of recurrent glioblastoma (GBM).
|
29782366 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Herein, we reported a novel dual-targeting therapy for glioblastoma through simultaneous blockade of VEGF and CD47 signaling.
|
29754163 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrate for the first time that VEGF is a modulator of the innate immune response with suppressive effects on the immunologic and pro-angiogenic function of microglia/macrophages in a glioblastoma rodent model.
|
28948650 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), is approved for treatment of metastatic colorectal cancer, nonsquamous non-small-cell lung cancer, metastatic kidney cancer, and glioblastoma.
|
29574193 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, the recombinant protein Flag-L-VEGF144 and commercial VEGF protein have similar growth stimulatory activities in terms of inducing glioblastoma cell proliferation in vitro.
|
29909500 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data reported that ASA affected GBM-EC viability, tube-like structure formation, cell migration, and VEGF releasing in a dose-dependent manner and that combined treatments with TMZ, BEV, and SUN synergized to counteract proangiogenic cell ability. mRNA expression analysis displayed a marked effect of ASA in reducing VEGF, VEGFR-1, HIF-1α, RAS, mitogen-activated protein kinase kinase, AKT, and BCL-2, as well a combined anticancer effect of ASA together with TMZ, BEV, and SUN.
|
30144594 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In particular, the reliance of GBM on angiogenesis triggered the development of anti-VEGF (vascular endothelial growth factor) blocking antibodies such as bevacizumab.
|
30065025 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combining CGKRK-LIGHT with anti-vascular endothelial growth factor and checkpoint blockade amplified HEV frequency and T-cell accumulation in GBM, which is often sparsely infiltrated by immune effector cells, and reduced tumour burden.
|
29603739 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastomas are rich in blood vessels (i.e. highly vascular) and also rich in a protein known as vascular endothelial growth factor (VEGF) that promotes new blood vessel formation (the process of angiogenesis).
|
30480778 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, nanohydrogel of quercetin was able to reduce significantly IL-8, IL-6, and VEGF production in pro-inflammatory conditions with interesting implications on the mechanism of glioblastoma cells drug resistance.
|
29030990 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
|
28668888 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
|
27942839 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastoma cancer stem-like cells (GCSCs) promote themselves proliferation by secreting the vascular endothelial growth factor A (VEGF<sub>A</sub>) in an autocrine manner, positively regulated by phosphodiesterase IV (PDE4).
|
28202289 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bevacizumab (Bev), a humanized anti-VEGF antibody, is associated with the improvement of progression-free survival and performance status in patients with glioblastoma.
|
28386777 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show that VEGF pathway blockade resulted in tumor growth retardation and inhibition of tumor vasculature in preclinical models of pediatric glioblastoma and breast cancer brain metastases, suggesting that multiparametric MRI can provide a powerful adjunct to accelerate the development of antiangiogenic therapies for use in these patient populations.
|
28780387 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
D16F7 reduced migration and invasion of VEGFR-1 positive GBM cell lines and patient-derived GSCs in response to VEGF-A and PlGF.
|
28797294 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.
|
28287096 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In xenograft models and patient specimens, we identified a c-Met/β1 integrin complex that formed during significant invasive oncologic processes: breast cancer metastases and glioblastoma invasive resistance to antiangiogenic VEGF neutralizing antibody, bevacizumab.
|
28973887 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Six initial and recurrent tumor pairs after bevacizumab (Bev) treatment were compared with GBMs from nine patients resected under neoadjuvant Bev treatment with regard to histological characteristics; MVD; MIB-1 index; and expression of vascular endothelial growth factor (VEGF) and its receptors, hypoxia markers (hypoxia-inducible factor 1 alpha, carbonic anhydrase 9), and nestin as a marker of glioma stem-like cells.
|
29262608 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The FDA approved the VEGF inhibitor bevacizumab-awwb for the treatment of five types of cancer: nonsquamous non-small cell lung cancer, metastatic colorectal cancer, cervical cancer, renal cell carcinoma, and glioblastoma.
|
28982661 |
2017 |